Coherus Oncology, Inc. (CHRS) Stock Analysis and Metrics

Coherus Oncology

NASDAQ: CHRS

$1.41 ▼ -0.02 (-1.40%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap194.37 Mn

P/E0.54

P/S4.15

Div. Yield0.00

Total Debt (Qtr)37.15 Mn

Revenue Growth (1y) (Qtr)61.99

Add ratio to table…

About

Coherus Oncology, Inc. is a fully integrated commercial stage oncology company focused on the development and commercialization of immuno oncology therapies. The company's lead product is LOQTORZI, an anti PD 1 antibody approved for the treatment of metastatic or recurrent nasopharyngeal carcinoma. LOQTORZI works by binding to the PD 1 receptor and blocking its interaction with PD L1 and PD L2 ligands, thereby helping the immune system recognize and attack tumor cells. In addition to LOQTORZI, Coherus Oncology advances a pipeline of two clinical stage candidates: casdozokitug targets the immune regulatory cytokine IL 27 to counteract immune suppression in hepatocellular carcinoma, while tagmokitug targets CCR8 on regulatory T cells to reduce immune tolerance in head and neck squamous cell carcinoma and other solid tumors.

Coherus Oncology, Inc. generates revenue primarily from the sale of LOQTORZI in the United States and Puerto Rico through wholesale distributors. Product sales are made to major wholesalers who then distribute LOQTORZI to oncology clinics, hospitals, and specialty pharmacies. The company also receives licensing fees, milestone payments, and royalties from collaboration agreements such as the agreement with Apotex for the commercialization of LOQTORZI in Canada. Additional revenue may arise from future milestones and royalties tied to the development and potential commercialization of its pipeline candidates casdozokitug and tagmokitug.

The company operates through the following segments:

• Reportable Segment: This segment encompasses all research development manufacturing and commercialization activities for Coherus Oncology, Inc.'s immuno oncology portfolio including LOQTORZI, casdozokitug, and tagmokitug.

Coherus Oncology, Inc. holds a distinct position in the immuno oncology market as the only FDA approved therapy specifically indicated for nasopharyngeal carcinoma in the United States. While it competes with established PD 1/PD L1 inhibitors such as Keytruda pembrolizumab from Merck, Opdivo nivolumab from Bristol Myers Squibb, Tecentriq atezolizumab from Genentech, and others, its early line approval in combination with chemotherapy and its preferential placement in NCCN guidelines provide a competitive advantage. The company's pipeline candidates have received special designations; casdozokitug obtained orphan drug status from the FDA for hepatocellular carcinoma and tagmokitug is being evaluated in multiple early stage trials for head and neck squamous cell carcinoma and other solid tumors. These factors, together with its expertise in immuno oncology research and its ability to combine novel mechanisms with existing checkpoint inhibitors, position Coherus Oncology to capture value in niche oncology indications.

Coherus Oncology, Inc. sells LOQTORZI to major wholesale distributors including McKesson Corporation, Cencora Inc, and Cardinal Health Inc. These distributors supply the product to oncology clinics, hospitals, and specialty pharmacies across the United States and Puerto Rico. The company also works with healthcare providers and treatment centers that administer LOQTORZI to patients with nasopharyngeal carcinoma.

Investment Thesis

▲ Bull case

CHRS's strategic focus on expanding Loqtorzi beyond nasopharyngeal carcinoma represents a significant undervalued opportunity, as the company is actively pursuing label expansions through proprietary combinations like casdozoketug in liver cancer and other indications, which management emphasized as a 'revenue multiplier' with built-in label extension for Loqtorzi upon any approval. The CEO explicitly noted that Loqtorzi alone can cover core cash burn at peak nasopharyngeal share ($175 million annually), but the real value driver lies in these combinations, which could unlock the stated $33 billion market opportunity by transforming Loqtorzi from a single-indication asset into a platform therapy with commercial synergies across multiple high-prevalence cancers. This approach de-risks revenue dependence on nasopharyngeal carcinoma while creating multiple pathways to sustained growth that the market appears to be overlooking in favor of near-term quarterly fluctuations.
The company's Treg depletion platform via tagmoketug, particularly through the J&J pasrutinib T cell engager combination in prostate cancer, presents a high-conviction catalyst that management did not fully highlight despite its strategic importance. Dennis Lanfear described Treg depletion as a 'foundational platform' and not merely a checkpoint adjunct, with plans to broadly deploy tagmoketug across cancers and nonproprietary therapies like ADCs and radiotherapy. The recent progress on the J&J collaboration—including anticipated first patient enrollment this fall—was presented as enabling efficient addition of further combination cohorts under a single protocol, suggesting a scalable, capital-efficient path to validating CCR8 depletion's therapeutic potential in large indications where current standards of care are inadequate, such as microsatellite stable colorectal cancer.
CHRS's commercial execution for Loqtorzi is demonstrating stronger underlying momentum than recent quarterly sales suggest, driven by structural shifts in prescribing behavior that management confirmed through expanded claims data visibility. Sameer Goregaoker reported all-time high new patient starts in Q1 2026 fueled by broader prescribing in new accounts and deeper use in existing ones, with overall ordering account breadth and depth increasing 21% and treatment duration rising quarter-over-quarter. Crucially, the company now has visibility into chemo-only and off-label PD-1 use across up to 70% of addressable patients, enabling targeted investments to correct guideline misperceptions and reinforce Loqtorzi's position as the only approved immunotherapy in nasopharyngeal carcinoma—a lever for growth that is being actively pursued through AI-driven HCP platforms and EMR initiatives, yet remains underappreciated in current revenue guidance.
The financial flexibility gained from the $54 million follow-on equity offering is being deployed with precise strategic intent toward near-term inflection points, a fact underscored by Bryan McMichael's explanation that proceeds are strengthening liquidity to fund key data readouts in 2026 and 2027, including the tagmoketug CRC and prostate studies and enhanced Loqtorzi commercialization. Management explicitly stated they believe they are 'sufficiently funded through key data readouts in 2026 and 2027,' eliminating a common biotech financing overhang and positioning the company to capitalize on imminent clinical milestones—such as midyear data from the CATALYST-202 HCC study and second-line head and neck/gastric tagmoketug trials—without dilution concerns, which reduces perceived risk ahead of potential value-accretive outcomes.

CHRS's strategic focus on expanding Loqtorzi beyond nasopharyngeal carcinoma represents a significant undervalued opportunity, as the company is actively pursuing label expansions through proprietary combinations like casdozoketug in liver cancer and other indications, which management emphasized as a 'revenue multiplier' with built-in label extension for Loqtorzi upon any approval. The CEO explicitly noted that Loqtorzi alone can cover core cash burn at peak nasopharyngeal share ($175 million annually), but the real value driver lies in these combinations, which could unlock the stated $33 billion market opportunity by transforming Loqtorzi from a single-indication asset into a platform therapy with commercial synergies across multiple high-prevalence cancers. This approach de-risks revenue dependence on nasopharyngeal carcinoma while creating multiple pathways to sustained growth that the market appears to be overlooking in favor of near-term quarterly fluctuations.
The company's Treg depletion platform via tagmoketug, particularly through the J&J pasrutinib T cell engager combination in prostate cancer, presents a high-conviction catalyst that management did not fully highlight despite its strategic importance. Dennis Lanfear described Treg depletion as a 'foundational platform' and not merely a checkpoint adjunct, with plans to broadly deploy tagmoketug across cancers and nonproprietary therapies like ADCs and radiotherapy. The recent progress on the J&J collaboration—including anticipated first patient enrollment this fall—was presented as enabling efficient addition of further combination cohorts under a single protocol, suggesting a scalable, capital-efficient path to validating CCR8 depletion's therapeutic potential in large indications where current standards of care are inadequate, such as microsatellite stable colorectal cancer.
CHRS's commercial execution for Loqtorzi is demonstrating stronger underlying momentum than recent quarterly sales suggest, driven by structural shifts in prescribing behavior that management confirmed through expanded claims data visibility. Sameer Goregaoker reported all-time high new patient starts in Q1 2026 fueled by broader prescribing in new accounts and deeper use in existing ones, with overall ordering account breadth and depth increasing 21% and treatment duration rising quarter-over-quarter. Crucially, the company now has visibility into chemo-only and off-label PD-1 use across up to 70% of addressable patients, enabling targeted investments to correct guideline misperceptions and reinforce Loqtorzi's position as the only approved immunotherapy in nasopharyngeal carcinoma—a lever for growth that is being actively pursued through AI-driven HCP platforms and EMR initiatives, yet remains underappreciated in current revenue guidance.
The financial flexibility gained from the $54 million follow-on equity offering is being deployed with precise strategic intent toward near-term inflection points, a fact underscored by Bryan McMichael's explanation that proceeds are strengthening liquidity to fund key data readouts in 2026 and 2027, including the tagmoketug CRC and prostate studies and enhanced Loqtorzi commercialization. Management explicitly stated they believe they are 'sufficiently funded through key data readouts in 2026 and 2027,' eliminating a common biotech financing overhang and positioning the company to capitalize on imminent clinical milestones—such as midyear data from the CATALYST-202 HCC study and second-line head and neck/gastric tagmoketug trials—without dilution concerns, which reduces perceived risk ahead of potential value-accretive outcomes.

▼ Bear case

CHRS's reliance on nasopharyngeal carcinoma for near-term cash flow remains a critical vulnerability, as Loqtorzi's peak annual revenue potential of $175 million is explicitly tied to achieving and sustaining maximum share in this indication—a goal that faces persistent headwinds from entrenched chemo-only use and off-label PD-1 inhibitors, despite management's efforts to educate on NCCN guidelines. Sameer Goregaoker acknowledged that reducing chemo-only use and curbing off-label IO use are ongoing levers for growth, implying these behaviors are still prevalent and actively undermining Loqtorzi's adoption, with the company only now gaining visibility into these patterns across up to 70% of patients, suggesting prior commercial efforts were blind to a significant portion of the addressable market. This dependency creates a scenario where failure to convert even a modest share of off-label or chemo-only patients could delay revenue targets by multiple quarters, especially given the modest 10-15% quarterly demand growth guidance for 2026.
The clinical progress of tagmoketug, while pharmacologically sound, faces significant competitive and biological headwinds that management downplayed by focusing on internal data strengths rather than external validation challenges. Theresa Lavallee acknowledged that the CCR8 field is bifurcating, with some programs pausing due to drug-like property failures while others advance, yet she failed to address why tagmoketug might still fail in vivo despite meeting in vitro pharmacological criteria—particularly given that CCR8's role as a GPCR makes selective targeting notoriously difficult, a challenge reinforced by Amgen's halted program after minimal responses in 77 patients. The company's expansive development strategy across tumor types and combinations risks spreading resources thin without clear differentiation from competitors like Gilead, whose dedikitug is already advancing in phase two, raising doubts about tagmoketug's ability to achieve meaningful differentiation in crowded indications where Treg depletion's therapeutic window remains unproven.
CHRS's guidance for Loqtorzi revenue growth appears overly optimistic when reconciled with the seasonal and operational realities disclosed in the earnings call, as Sameer Goregaoker revealed that Q1 2026's 10% quarter-over-quarter decline in an oncology basket (vs. a historical 5%) was driven by severe winter storms that disrupted treatment cycles for existing patients—a dynamic he explicitly stated would not be recovered, noting that missed cycles result in permanent loss rather than deferral. This admission undermines the confidence in reaching $30-35 million per quarter by 2027, especially since the company's growth model depends on converting new starts into long-term existing patients, yet weather-related disruptions are eroding the very base they seek to expand, with no mechanism to recoup lost revenue cycles.
The pipeline's dependence on early biomarker signals like IL-27 expression and circulating tumor DNA introduces substantial execution risk, as Theresa Lavallee conceded that the prior casdozoketug HCC study had only seven evaluable tumor samples (25% of patients) for IL-27 analysis, yet the company is now building pivotal study readout expectations around these same biomarkers in the fully enrolled CATALYST-202 trial. Given that delayed responses in hepatocellular carcinoma necessitate longer follow-up for survival endpoints, relying on immature surrogate markers like circulating tumor DNA—whose correlation with solid tumor outcomes remains unvalidated despite its use in hematological malignancies—increases the likelihood of false-positive early signals that fail to mature into clinically meaningful efficacy, potentially triggering premature celebration followed by disappointing later-stage results that could devastate investor confidence.

CHRS's reliance on nasopharyngeal carcinoma for near-term cash flow remains a critical vulnerability, as Loqtorzi's peak annual revenue potential of $175 million is explicitly tied to achieving and sustaining maximum share in this indication—a goal that faces persistent headwinds from entrenched chemo-only use and off-label PD-1 inhibitors, despite management's efforts to educate on NCCN guidelines. Sameer Goregaoker acknowledged that reducing chemo-only use and curbing off-label IO use are ongoing levers for growth, implying these behaviors are still prevalent and actively undermining Loqtorzi's adoption, with the company only now gaining visibility into these patterns across up to 70% of patients, suggesting prior commercial efforts were blind to a significant portion of the addressable market. This dependency creates a scenario where failure to convert even a modest share of off-label or chemo-only patients could delay revenue targets by multiple quarters, especially given the modest 10-15% quarterly demand growth guidance for 2026.
The clinical progress of tagmoketug, while pharmacologically sound, faces significant competitive and biological headwinds that management downplayed by focusing on internal data strengths rather than external validation challenges. Theresa Lavallee acknowledged that the CCR8 field is bifurcating, with some programs pausing due to drug-like property failures while others advance, yet she failed to address why tagmoketug might still fail in vivo despite meeting in vitro pharmacological criteria—particularly given that CCR8's role as a GPCR makes selective targeting notoriously difficult, a challenge reinforced by Amgen's halted program after minimal responses in 77 patients. The company's expansive development strategy across tumor types and combinations risks spreading resources thin without clear differentiation from competitors like Gilead, whose dedikitug is already advancing in phase two, raising doubts about tagmoketug's ability to achieve meaningful differentiation in crowded indications where Treg depletion's therapeutic window remains unproven.
CHRS's guidance for Loqtorzi revenue growth appears overly optimistic when reconciled with the seasonal and operational realities disclosed in the earnings call, as Sameer Goregaoker revealed that Q1 2026's 10% quarter-over-quarter decline in an oncology basket (vs. a historical 5%) was driven by severe winter storms that disrupted treatment cycles for existing patients—a dynamic he explicitly stated would not be recovered, noting that missed cycles result in permanent loss rather than deferral. This admission undermines the confidence in reaching $30-35 million per quarter by 2027, especially since the company's growth model depends on converting new starts into long-term existing patients, yet weather-related disruptions are eroding the very base they seek to expand, with no mechanism to recoup lost revenue cycles.
The pipeline's dependence on early biomarker signals like IL-27 expression and circulating tumor DNA introduces substantial execution risk, as Theresa Lavallee conceded that the prior casdozoketug HCC study had only seven evaluable tumor samples (25% of patients) for IL-27 analysis, yet the company is now building pivotal study readout expectations around these same biomarkers in the fully enrolled CATALYST-202 trial. Given that delayed responses in hepatocellular carcinoma necessitate longer follow-up for survival endpoints, relying on immature surrogate markers like circulating tumor DNA—whose correlation with solid tumor outcomes remains unvalidated despite its use in hematological malignancies—increases the likelihood of false-positive early signals that fail to mature into clinically meaningful efficacy, potentially triggering premature celebration followed by disappointing later-stage results that could devastate investor confidence.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password